[Research Progress of Immunotherapy for Non-small Cell Lung Cancer 
with Drive Gene Mutation]

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality worldwide, representing 80% of all lung cancer cases.
• While targeted therapies are effective for NSCLC with driver gene mutations, some patients experience disease progression or relapse.
• Immune checkpoint inhibitors (ICIs) have shown potential in improving prognosis and survival for advanced NSCLC.

Purpose of the Study:

• To review the immune characteristics of NSCLC patients harboring driver gene mutations.
• To explore the efficacy and potential directions of immunotherapy in this specific patient subgroup.

Main Methods:

• Literature review of studies on NSCLC, driver gene mutations, and immunotherapy.
• Analysis of immune profiles and treatment responses in NSCLC patients with driver mutations.

Main Results:

• Efficacy of immunotherapy, including ICIs, varies significantly among NSCLC patients based on their immune and molecular features.
• The role and effectiveness of immunotherapy in NSCLC patients with driver gene mutations remain a subject of ongoing research and debate.

Conclusions:

• Understanding the immune landscape of NSCLC with driver mutations is crucial for optimizing immunotherapy strategies.
• Further research is needed to identify predictive biomarkers and refine treatment approaches for personalized immunotherapy in NSCLC patients with driver mutations.